Jaguar Health (JAGX) Convertible Debt (2017 - 2018)
Jaguar Health (JAGX) posted quarterly Convertible Debt of $10.7 million for Q3 2018, down 4.48% year-over-year from $11.2 million in Q3 2017, and down 2.93% quarter-over-quarter from $11.0 million in Q4 2017.
Jaguar Health (JAGX) Convertible Debt (2017 - 2018) Analysis & Trends
Jaguar Health (JAGX) has reported Convertible Debt for 2 consecutive years, with $10.7 million the latest figure, recorded in Q3 2018.
- In Q3 2018, Convertible Debt fell 4.48% year-over-year to $10.7 million; the TTM figure through Sep 2018 stood at $10.7 million (down 4.48% YoY), while the FY2017 annual figure was $11.0 million, changed N/A from the prior year.
- Convertible Debt declined to $10.7 million in Q3 2018 per JAGX's latest filing, from $11.0 million in the prior quarter.
- Across five years, Convertible Debt topped out at $11.2 million in Q3 2017 and bottomed at $10.7 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Jaguar Health | 457,761.84 | -9.61 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 10.66 Mn |
| Dec 31, 2017 | 10.98 Mn |
| Sep 30, 2017 | 11.16 Mn |